CEO Interview Interim Results 2025 – Acrobat pdf 125k 13 February 2025 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: First half results Implementations and contract trends North American TAM and market segments Elucid, AI and other ologies Recent wins and pipeline
13 February 2025; Company Announcement - Half Year Results 2025 - Acrobat pdf 363k Highlights Revenue from ordinary activities $97.2m – up 31.1% Underlying profit before tax $69.9m – up 42.9% Net profit $51.7m – up 42.7% Underlying EBIT margins increase to 72% (HY24: 66%) Cash and other financial assets $182.3m – up 17.7% Company remains debt-free Fully franked interim dividend 25c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a half-year net profit of $51.7 million for the six months to the end of December 2024, 42.7% higher than for the previous corresponding period. Revenue from ordinary activities was $97.2 million, up 31.1%. The result was driven largely by increased revenue from North America (revenue $86.4 million, up 34.6%). The company’s cash and other financial assets in December 2024 were $182.3 million, an increase of 17.7% in the six months. Pro Medicus announced a fully franked interim dividend of 25c per share. The company remains debt-free. During the period Pro Medicus won key contracts with Trinity Health, Lurie Children’s Hospital and Duly Health and Care. These contracts were for a combined minimum amount of $365 million spread over 7-10-year deals. In addition, the company renewed contracts with Mercy Health in the USA ($98 million, 8 years) and with a large Australian radiology practice ($32 million, 5 years). Additional modules were also added to existing contracts at both Duke Health (archive addition, $15 million, 5 years) and NYU Langone (archive addition, $24 million, 5 years). Pro Medicus CEO Dr Sam Hupert said he was very pleased with the result, which was a record one for the company in terms of both revenue and net profit, as well as new
CEO Interview - Full Year Results 2024 – Acrobat pdf 214k 14 August 2024 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: Full-Year results Sales and implementation update Market segmentation and factors driving the industry Pipeline
14 August 2024; Company Announcement - Full-Year Results 2024 - Acrobat pdf 364k Highlights Revenue from ordinary activities $161.5m – up 29.3% Underlying profit before tax $116.5m – up 35.3% Net profit $82.8m – up 36.5% Underlying EBIT margins increase to 69.5% (FY23: 67.2%) Cash and other financial assets $155.4m – up 27.9% Company remains debt-free Fully franked final dividend 22c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full-year net profit of $82.8 million for the year to the end of June 2024, 36.5% higher than for the previous corresponding period. Revenue from ordinary activities was $161.5 million, up 29.3%. The company’s cash and other financial assets at the end of June 2024 were $155.4 million, up $33.9 million, an increase of 27.9%. Pro Medicus announced a fully franked final dividend of 22c per share, making the full year dividend 40c fully franked, an increase of 33.3%. The company remains debt-free. The result was driven by increased revenue from North America up 34.4% and Australia up 5.9%, whilst Europe decreased by 6.7% due to one-off revenue from a sale to a German hospital in the previous corresponding period. During the year Pro Medicus made the following key announcements: A $24M, 7-year contract with Memorial Sloan Kettering Cancer Centre, a not-for-profit cancer centre that operates 24 inpatient and outpatient locations across the New York City metropolitan region. A $140M, 10-year contract with Baylor, Scott and White, the largest not-for-profit health care system in Texas, and one of the largest in the United States. A $16M, 8-year contract with South Shore Health, the largest independent health system in Southeastern Massachusetts. A $20M, 8-year contract with Oregon Health & Science
CEO Interview - HY24 Results – Acrobat pdf 409k 15 February 2024 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: Commentary on first half results Contract trends and implementation update USD $5M Elucid investment and view on M&A Launch of Visage Ease VP for Apple Vision Pro Recent wins and pipeline
15 February 2024; Company Announcement: Pro Medicus Limited Interim Results - Acrobat pdf 358k Highlights Revenue from ordinary activities $74.1m – up 30.3% Underlying profit before tax $48.9m – up 31.5% Net profit $36.3m – up 33.3% Cash and other financial assets $131.5m – up 8.3% Company remains debt-free Fully-franked interim dividend 18c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a half-year net profit of $36.3 million for the six months to the end of December 2023, 33.3% higher than for the previous corresponding period. Revenue from ordinary activities was $74.1 million, up 30.3%. The company’s cash and other financial assets at December 2023 were $131.5 million, an increase of 8.3%. Pro Medicus announced a fully-franked interim dividend of 18c per share. The company remains debt-free. The result was largely driven by increased revenue from North America (revenue up 36.8%), with four major implementations completed. During the six-month period Pro Medicus also won four key contracts; Memorial Sloan Kettering, Baylor Scott & White, South Shore Health and Oregon Health & Science University. These contracts have a total contract value of A$200 million (at committed minimum exam volumes) with contract terms ranging from 7 to 10 years. Pro Medicus CEO Dr Sam Hupert said he was very pleased with the result, which was a record one for the company in terms of revenue and net profit as well as new sales. “We benefited from above industry growth in exam volumes across our client base and successfully completed four new implementations all of which will provide a full six months of revenue in the second half. On top of this, we had our strongest start to the year in terms
5 February 2024; Company Announcement Visage Ease VP Launch Final - Acrobat pdf 826k Highlights Visage has launched the groundbreaking Visage Ease VP for Apple Vision Pro Visage Ease VP supports immersive, spatial experiences for diagnostic imaging and multimedia Visage’s cinematic rendering engine is natively available in Visage Ease VP providing stunning volume-rendered images in immersive space Visage Ease VP provides an end-user imaging experience that’s unlike any other application Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has announced the launch of the groundbreaking Visage Ease VP for Apple Vision Pro, Apple’s highly anticipated spatial computing platform. Designed to take advantage of the unique capabilities of Apple Vision Pro, Visage Ease VP supports immersive, spatial experiences for diagnostic imaging and multimedia. Visage Ease VP includes all the proven functionality of Visage Ease™, plus the exciting addition of Visage’s powerful cinematic rendering engine for stunning volume-rendered images in immersive space. Anywhere, on-the-go access with Visage Ease VP has additional flexibility with virtual screens at more than 4K resolution for each eye, independence from environmental lighting restrictions, and the ability to interact with imaging seamlessly in your physical space. Visage Ease VP uses the natural and intuitive input of eyes, hands, and voice navigation to provide an end-user imaging experience that’s unlike any other application. UC San Diego Health, a Tier 1 academic medical center and Visage customer, is the first health system to pilot the technology. “The visualization of three-dimensional medical imaging in immersive space creates exciting opportunities to improve patient care,” said Dr. Paul Murphy, associate clinical professor at UC San Diego School of Medicine and radiologist at UC San Diego Health. “Technology
CEO Interview - FY23 Annual Results – Acrobat pdf 432k 15 August 2023 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: Full-year results Sales and implementation update Market segmentation and factors driving the industry Pipeline
15 August 2023; Company Announcement - FY Results Final - Acrobat pdf 200k Highlights Revenue from ordinary activities $124.9m – up 33.6% Net profit $60.6m – up 36.5% Cash and other financial assets $121.5m – up 34.2% Company remains debt-free Fully-franked final dividend 17c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full-year net profit of $60.6m for the year to the end of June 2023, 36.5% higher than for the previous corresponding period. Revenue from ordinary activities increased by 33.6% to $124.9 million. The company’s cash and other financial assets at June 2023 were $121.5 million, up $30.9 million, an increase of 34.2%. Pro Medicus announced a fully-franked final dividend of 17c per share, making the full year-dividend 30c fully-franked, an increase of 36.4%. The company remains debt-free. The result was driven by increased revenue from North America up 41.8% and Australia up 9.4% whilst Europe decreased by 12.2% due to one-off revenue coming from the extension of the German government hospital contract in FY22 year which was not replicated this year. During the year Pro Medicus made the following key announcements: Three contract wins with a combined minimum value of $16.5m - Montage Health, Children’s Hospital of Philadelphia (CHOP), and Bay Imaging Consultants. The University of Florida contract renewal for another seven years, with a minimum contract value of $15.5m. A $15M, 8-year contract with Luminis Health, a not-for-profit integrated delivery network (IDN) healthcare provider in Annapolis, Maryland. A $25M, 7-year contract with University of Washington, a leading teaching hospital in the University District of Seattle. A $12M, 8-year contract with Samaritan Health, a not-for-profit network of hospitals and health services in central Oregon. A $20M,
16 May 2023; Company Announcement - Gundersen Final - Acrobat pdf 437k Highlights PME signs 7-year, AUD $20M deal with Gundersen Health System (“Gundersen”) Visage to replace legacy PACS throughout the Gundersen network Contract is for “full stack” - Visage 7 Viewer, Visage 7 Open Archive and Visage 7 Workflow Visage 7 platform to be implemented in the cloud Continues PME’s rapid expansion into North American integrated delivery networks Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has signed a $20M, 7-year contract with Gundersen Health System, a not-for-profit integrated delivery network (IDN), comprising seven (7) hospitals and 65 clinics across Wisconsin, Minnesota and Iowa. Based on a transactional licensing model, the contract will see the company’s cloud-engineered Visage 7 Enterprise Imaging Platform (‘Visage 7’), including Visage 7 Open Archive and Visage 7 Workflow modules, implemented throughout Gundersen providing a unified diagnostic imaging platform across the network. Planning for the rollout is to commence immediately and will be based on Visage’s proven cloud-based implementation process, with initial go-lives targeted for the second half of the 2023 calendar year. “IDNs are the largest market segment in North America and we continue to build strong momentum in this key market with this, our fifth material IDN contract in the last 12 months, “ said Dr Sam Hupert, Pro Medicus CEO. “It reinforces our belief that our solution is equally well suited to IDNs of all sizes, making our total addressable market very significant.” Gundersen joins the increasing list of consecutive Visage 7 clients to opt for a fully cloud-engineered solution, a trend that has now become the standard in the North